GEN Exclusives

More »

GEN Poll

More »
Jan 16, 2012

U.K. Biotech Strategy

Intent on shepherding more biopharma companies to market and keeping them growing, Prime Minister David Cameron recently unveiled a “Strategy for UK Life Sciences”. The strategy calls for the U.K. to launch a £180 million ($278.6 million) fund to push startup companies past the “valley of death,” a £130 million ($201.2 million) personalized medicine research fund, and a £50 million ($77.4 million) cell therapy technology center, among other components. The strategy also promises a new initiative to speed up approvals of new drugs. “We must ensure that the U.K. stays ahead,” Cameron said. Do you think the Strategy will help the U.K. reach its goals for biotechnology?

How much do you think the new Strategy will succeed in enhancing the U.K.’s competitiveness in biopharma?

A great deal
Not much

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »